|
1
|
Rauf MS, Akhtar S and Maghfoor I: Changing
trends of adult lymphoma in the kingdom of Saudi Arabia-comparison
of data sources. Asian Pac J Cancer Prev. 16:2069–2072. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leukemia and Lymphoma Society, . American
Cancer Society Cancer Facts and Figures 2016; GLOBOCAN 2012;
ClinicalTrials.gov. CRI grantee progress reports and other CRI
grantee documents. 2016, http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lymphoma#sthash.9EkuimDH.dpuf
91November 14–2014
|
|
3
|
Al-Madouj AN, Eldali A and Al-Zahrani AS:
Ten year cancer incidence among nationals of the GCC states. Gulf
center for cancer control and prevention, king faisal specialist
hospital and research center. 2011, http://www.moh.gov.bh/Content/Files/Publications/GCC%20Cancer%20Incidence%202011.pdfSeptember
1–2011
|
|
4
|
Cancer Incidence Report Saudi Arabia 2013,
. http://www.chs.gov.sa/Ar/HealthCenters/NCC/CancerRegistry/CancerRegistryReports/2013June
1–2016
|
|
5
|
Maggioncalda A, Malik N, Shenoy P, Smith
M, Sinha R and Flowers CR: Clinical, molecular, and environmental
risk factors for Hodgkin lymphoma. Adv Hematol. 2011:7362612011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Al-Diab AI, Siddiqui N, Sogiawalla FF and
Fawzy EM: The changing trends of adult Hodgkin's disease in Saudi
Arabia. Saudi Med J. 24:617–622. 2003.PubMed/NCBI
|
|
7
|
Piccaluga PP, Agostinelli C, Gazzola A,
Tripodo C, Bacci F, Sabattini E, Sista MT, Mannu C, Sapienza MR,
Rossi M, et al: Pathobiology of hodgkin lymphoma. Adv Hematol.
2011:9208982011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montes-Moreno S: Hodgkin's lymphomas: A
tumor recognized by its microenvironment. Adv Hematol.
2011:1423952011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith LB: Nodular lymphocyte predominant
Hodgkin lymphoma: Diagnostic pearls and pitfalls. Arch Pathol Lab
Med. 134:1434–1439. 2010.PubMed/NCBI
|
|
10
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
11
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin's disease. International prognostic
factors project on advanced Hodgkin's disease. N Engl J Med.
339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Canioni D, Deau-Fischer B, Taupin P,
Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B,
et al: Prognostic significance of new immunohistochemical markers
in refractory classical Hodgkin lymphoma: A study of 59 cases. PLoS
One. 4:e63412009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moccia AA, Donaldson J, Chhanabhai M,
Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider
B, Gascoyne RD, et al: International prognostic score in
advanced-stage Hodgkin's lymphoma: Altered utility in the modern
era. J Clin Oncol. 30:3383–3388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Henry-Amar M, Friedman S, Hayat M, Somers
R, Meerwaldt JH, Carde P, Burgers JM, Thomas J, Monconduit M and
Noordijk EM: Erythrocyte sedimentation rate predicts early relapse
and survival in early-stage Hodgkin disease. The EORTC lymphoma
cooperative group. Ann Intern Med. 114:361–365. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roshal M, Wood BL and Fromm JR: Flow
cytometric detection of the classical hodgkin lymphoma: Clinical
and research applications. Adv Hematol. 2011:3870342011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dunphy CH: Applications of flow cytometry
and immunohistochemistry to diagnostic hematopathology. Arch Pathol
Lab Med. 128:1004–1022. 2004.PubMed/NCBI
|
|
17
|
Scott DW and Steidl C: The classical
Hodgkin lymphoma tumor microenvironment: Macrophages and gene
expression-based modeling. Hematology Am Soc Hematol Educ Program.
2014:144–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan KL, Scott DW, Hong F, Kahl BS, Fisher
RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, et
al: Tumor-associated macrophages predict inferior outcomes in
classic Hodgkin lymphoma: A correlative study from the E2496
Intergroup trial. Blood. 120:3280–3287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mallmann MR, Schmidt SV and Schultze JL:
Macrophages in human cancer: Current and future aspects. Atlas
Genet Cytogenet Oncol Haematol. 16:765–774. 2012.
|
|
20
|
Ruhrberg C and De Palma M: A double agent
in cancer: Deciphering macrophage roles in human tumors. Nat Med.
16:861–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ree HJ and Kadin ME:
Macrophage-histiocytes in Hodgkin's disease. The relation of
peanut-agglutinin-binding macrophage-histiocytes to
clinicopathologic presentation and course of disease. Cancer.
56:333–338. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo B, Cen H, Tan X and Ke Q:
Meta-analysis of the prognostic and clinical value of
tumor-associated macrophages in adult classical Hodgkin lymphoma.
BMC Med. 14:1592016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sud A, Thomsen H, Sundquist K, Houlston RS
and Hemminki K: Risk of second cancer in Hodgkin lymphoma survivors
and influence of family history. J Clin Oncol. 35:1584–1590. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Steidl C, Lee T, Shah SP, Farinha P, Han
G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al:
Tumor-associated macrophages and survival in classic Hodgkin's
lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sánchez-Espiridión B, Montalbán C, López
A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R,
Rodríguez J, Cánovas A, et al: A molecular risk score based on 4
functional pathways for advanced classical Hodgkin lymphoma. Blood.
116:e12–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gregory AD and Houghton AM:
Tumor-associated neutrophils: New targets for cancer therapy.
Cancer Res. 71:2411–2416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wahl LM and Kleinman HK: Tumor-associated
macrophages as target for cancer therapy. J Natl Cncer Inst.
90:1583–1584. 1998. View Article : Google Scholar
|
|
28
|
Derenzini E and Younes A: Predicting
treatment outcome in classical Hodgkin lymphoma: Genomic advances.
Genome Med. 3:262011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barros MH, Segges P, Vera-Lozada G, Hassan
R and Niedobitek G: Macrophage polarization reflects T cell
composition of tumor microenvironment in pediatric classical
Hodgkin lymphoma and has impact on survival. PLoS One.
10:e01245312015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoon DH, Koh YW, Kang HJ, Kim S, Park CS,
Lee SW, Suh C and Huh J: CD68 and CD163 as prognostic factors for
Korean patients with Hodgkin lymphoma. Eur J Haematol. 88:292–305.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Azambuja D, Natkunam Y, Biasoli I, Lossos
IS, Anderson MW, Morais JC and Spector N: Lack of association of
tumor-associated macrophages with clinical outcome in patients with
classical Hodgkin's lymphoma. Ann Oncol. 23:736–742. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lau SK, Chu PG and Weiss LM: CD163: A
specific marker of macrophages in paraffin-embedded tissue samples.
Am J Clin Pathol. 122:794–801. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ritter M, Buechler C, Langmann T, Orso E,
Klucken J and Schmitz G: The scavenger receptor CD163: Regulation,
promoter structure and genomic organization. Pathobiology.
67:257–261. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harris JA, Jain S, Ren Q, Zarineh A, Liu C
and Ibrahim S: CD163 versus CD68 in tumor associated macrophages of
classical Hodgkin lymphoma. Diagn Pathol. 7:122012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
El-Zein R, Monroy CM, Etzel CJ, Cortes AC,
Xing Y, Collier AL and Strom SS: Genetic polymorphisms in DNA
repair genes as modulators of Hodgkin disease risk. Cancer.
115:1651–1659. 2009. View Article : Google Scholar : PubMed/NCBI
|
